Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 368 participants.

Also called NCT01414920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 368 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01414920
  • WHO UTN U1111-1115-5044
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01414920. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
TAK-875
Intervention (Drug)
TAK-875
Intervention (Drug)
Sitagliptin
Intervention (Drug)
TAK-875 and Sitagliptin
Intervention (Drug)
TAK-875 and Sitagliptin
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01414920
Content hash
432828fd4916558dd8f0818d38afead1fdad635d8b5a288c3c459519ed4acf6b